The German etanercept registry for treatment of juvenile idiopathic arthritis.

Objective: To describe a registry set up to monitor children treated with etanercept in Germany and Austria.

Methods: Giannini's criteria, duration of morning stiffness, number of swollen, tender and contracted joints, adverse events, and reasons for discontinuation were assessed.

Results: 322 patients with juvenile idiopathic arthritis (JIA) and 12 additional patients with non-JIA rheumatic diagnoses were included.